Effect of Intralymphatic Immunotherapy

NCT02255604 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Allergy
Immune Tolerance
Injection Site Discomfort

Interventions

DRUG: Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
DRUG: alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
DRUG: 0.1 ml Isoton saline

Sponsor

University of Aarhus